WILSONVILLE, Ore. – November 5, 2018 – FLIR Systems, Inc. (NASDAQ: FLIR) announced today it has been awarded the first option phase on a five-year, cost-plus fixed fee contract by the United States Department of Defense’s Defense Threat Reduction Agency (DTRA). This option totals $1.2 million for continued development of the FLIR Agentase C2 chemical agent disclosure spray (ADS) for detection of nerve agents and a new formulation for fentanyl detection.
Under the contract, FLIR will demonstrate the benefits of electrostatic spraying technology and a new low-light additive on the operational utility of the existing nerve agent formulation. The Agentase C2 product line is used to visualize chemical threats on hardened military equipment (HME) for verification that trace amounts of chemicals have been decontaminated. It can also be used to map contamination when responding to clandestine labs and other chemical incidents.
“The FLIR Agentase C2 product line provides the capability to rapidly detect trace quantities of toxic, dangerous chemical threats, such as nerve agents and fentanyl variants, for safe and efficient mission performance,” said Dennis Barket, Jr., Vice President and General Manager of FLIR Detection. “This contract win solidifies our efforts to develop reliable hazmat solutions for warfighters to support programs of record.”
The timeframe for the first option phase is from August 15, 2018 through August 14, 2019, with three additional option years to follow. Work performed under this contract will take place at the FLIR Pittsburgh, Pa. facility.
FLIR is currently providing the Agentase C2 nerve agent disclosure spray and training formulation to the Joint Program Executive Office for Chem-Bio Defense (JPEO CBD), Joint Project Manager – Protection, under the Contamination Indicator/ Decontamination Assurance System (CIDAS) Program of Record. For more information about the Agentase C2 spray, visit www.flir.com/agentase-c2.